Generate Biomedicines Inc.
GENB | NASDAQ
$13.36
-$1.10 (-7.61%)
Nov 2, 2026, 2:34 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Net Income | -67.26M | -61.45M |
Depreciation & Amortization | 3.22M | 3.27M |
Stock-Based Compensation | 8.24M | n/a |
Other Working Capital | -2.5M | -34.41M |
Other Non-Cash Items | 2.31M | 8.44M |
Deferred Income Tax | n/a | n/a |
Change in Working Capital | -4.46M | -30.65M |
Operating Cash Flow | -57.94M | -80.39M |
Capital Expenditures | -933K | -3.78M |
Cash Acquisitions | n/a | 7.5M |
Purchase of Investments | -606K | -321.15M |
Sales Maturities Of Investments | 34.85M | 65M |
Other Investing Acitivies | n/a | n/a |
Investing Cash Flow | 33.31M | -252.43M |
Debt Repayment | -993K | -1.12M |
Common Stock Repurchased | n/a | n/a |
Dividend Paid | n/a | n/a |
Other Financial Acitivies | n/a | n/a |
Financial Cash Flow | -579K | 371.39M |
Net Cash Flow | -25.21M | 160.58M |
Free Cash Flow | -58.88M | -84.17M |
Adj. Free Cash Flow | -67.12M | -84.17M |
Maintenance CapEx | -933K | -3.27M |
Growth CapEx | n/a | -508K |
Owner Earnings | -58.88M | -83.66M |
Add to Watchlist
Select watchlists to add or remove GENB